on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Sets Course for Human Trials with Avance Clinical Agreement
Onco-Innovations Limited announced a Start-Up Agreement with Avance Clinical Pty Ltd to facilitate clinical trials for its Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This contract will aid in preparing essential regulatory documents needed for human testing. The collaboration focuses on advanced-stage cancers with PTEN1 or SHP-12 deficiencies.
Avance will offer regulatory and clinical expertise, developing key materials such as an Investigator's Brochure and a detailed clinical trial protocol. A nonclinical gap analysis by Avance will assess any remaining preclinical work, with plans for a pre-IND meeting with the FDA aimed at aligning trial design and reducing risks.
Onco's CEO, Thomas O'Shaughnessy, emphasized the significance of turning scientific research into clinical opportunities through this partnership.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news